США - англійська - NLM (National Library of Medicine)

stat rx usa llc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate 100 mg - orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo-skeletal conditions. the mode of action of the drug has not been clearly identified, but may be related to its analgesic properties. orphenadrine citrate does not directly relax tense skeletal muscles in man. contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis. contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

США - англійська - NLM (National Library of Medicine)

h.j. harkins company, inc. - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate 100 mg - orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo-skeletal conditions. the mode of action of the drug has not been clearly identified, but may be related to its analgesic properties. orphenadrine citrate does not directly relax tense skeletal muscles in man. contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis. contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

США - англійська - NLM (National Library of Medicine)

american health packaging - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate 100 mg - orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo-skeletal conditions. the mode of action of the drug has not been clearly identified, but may be related to its analgesic properties. orphenadrine citrate does not directly relax tense skeletal muscles in man. contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis. contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

США - англійська - NLM (National Library of Medicine)

h.j. harkins company, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 100 mg - bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder. a physician considering bupropion for the management of a patient’s first episode of depression should be aware that the drug may cause generalized seizures in a dose dependent manner with an approximate incidence of 0.4% (4/1,000). this incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. this relative risk is only an approximate estimate because no direct comparative studies have been conducted (see warnings). the efficacy of bupropion has been established in three placebo-controlled trials, including two of approximately 3 weeks’ duration in depressed inpatients and one of approximately 6 weeks’ duration in depressed outpatients. the depressive disorder of the patients studied corresponds most closely to the major depression category of the apa diagnostic and statistical manual iii. major depression implies a prominent and relatively persistent depressed or dysphoric mood t

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 75 mg - bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder. a physician considering bupropion for the management of a patient’s first episode of depression should be aware that the drug may cause generalized seizures in a dose dependent manner with an approximate incidence of 0.4% (4/1,000). this incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. this relative risk is only an approximate estimate because no direct comparative studies have been conducted (see warnings). the efficacy of bupropion has been established in three placebo-controlled trials, including two of approximately 3 weeks’ duration in depressed inpatients and one of approximately 6 weeks’ duration in depressed outpatients. the depressive disorder of the patients studied corresponds most closely to the major depression category of the apa diagnostic and statistical manual iii. major depression implies a prominent and relatively persistent depressed or dysp

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - orphenadrine hydrochloride - oral solution - 10mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - orphenadrine hydrochloride - oral solution - 5mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - orphenadrine hydrochloride - oral solution - 10mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - orphenadrine hydrochloride - oral solution - 10mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - orphenadrine hydrochloride - oral solution - 10mg/1ml